Clinical and Haematological Effects of Hydroxyurea in β-Thalassemia Intermedia Patients

It is well known that hydroxyurea (HU) impacts on clinical and haematologic indices in thalassemia. We aimed to evaluate the effect of hydroxyurea on clinical and haematological improvement in children with thalassemia intermedia. After the patients' enrollment in the study their data such as transfusion, hospitalization, spleen size, visit, total Hb, HbF levels, MCV and MCH were compared before and after treatment with HU 10 mg/kg/day/for one year. In patients with thalassemia intermedia, HU significantly diminished the rate of transfusion, hospitalization, spleen size and significantly increased Hb MCH, HbF and MCV. Moreover HU was well tolerated in our patients and we got no remarkable adverse effect. We divulged hydroxyurea 10 mg/kg/day during one year. This significantly increased HbF, total haemoglobin, MCV, MCH, without any remarkable adverse events.